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Tang-Her Jaing,1 Shih-Hsiang Chen,1 Ming Horng Tsai,1 Chao-Ping Yang,1 Iou-Jih Hung,1
Pei-Kwei Tsay2The potential benefits of unrelated donor bone marrow transplantation are offset by the immunologic com-
plications of graft-versus-host disease (GVHD) and infection. We used cryopreserved umbilical cord blood
(UCB) as a strategy to reduce the risks of GVHD and treatment-related mortality (TRM) and improved sur-
vival. Data on 45 patients with median age of 4.5 years who received transplants between October 2003 and
February 2009 for the treatment of nonmalignant diseases were evaluated. As of May 15, 2009, the median
follow-up was 25 months (range: 3-66). The majority (82%) of patients received an HLA-mismatched graft.
The median infused total nucleated cell dose was 7.6 107/kg and CD341 count 4.0 105/kg. Primary graft
failure was encountered after 4 transplantations (8%). Log-rank tests and Cox regression analyses were used
to determine the effects of various demographic, graft-related, and treatment factors on engraftment,
GVHD, TRM, graft failure, and survival. Incidences of neutrophil and platelet engraftment were 88% and
82%, respectively. The incidence of severe grade III-IV acute GVHD (aGVHD) was 42%. Five-year overall sur-
vival (OS) and disease-free survival (DFS) were 88.1% and 77.1%, respectively. The cumulative incidence of
TRM at 2 years was 12.0%. When cell dose and other factors are optimal, unrelated CBT is a promising ap-
proach for curative therapy of nonmalignant diseases.
Biol Blood Marrow Transplant 16: 102-107 (2010)  2010 American Society for Blood and Marrow TransplantationKEY WORDS: Unrelated cord blood transplantation, Nonmalignant diseases, Overall Survival, Disease-free
survival, Indications, PrognosisINTRODUCTION
Cord blood transplantation (CBT) has emerged as
a therapeutic option for a number of nonmalignant dis-
eases affecting the bone marrow (BM) and leading to
clinical manifestations, most likely affecting distant
organs. Advantages from unrelated donor umbilical
cord blood (UCB) donors such as faster availability,
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6/j.bbmt.2009.09.009of acute graft-versus-host disease (aGVHD) made
UCB transplants attractive for patients with some
nonmalignant diseases [1]. We used unrelated donor
UCB as a strategy to reduce the risks of GVHD and
treatment-related mortality (TRM) in children with
nonmalignant diseases. Our study was designed to ex-
plore the impact of innovations in transplant source
on results of hematopoietic stem cell transplantation.MATERIALS AND METHODS
Patients and Selection of Appropriate
Transplants
The study was in accordance with the principles of
the Declaration of Helsinki, and the appropriate ethi-
cal committee approved the work and proposed study
design. A parent or legal guardian provided informed
consent for each child before any trial-related treat-
ment began.
Underlyingdiseases includedtransfusion-dependent
thalassemia (SAA; n5 32), primary immunodeficiency
(n5 5), severe aplastic anemia (n5 3), infantile osteo-
petrosis (n5 3), and Fanconi’s anemia (FA; n5 2).
Biol Blood Marrow Transplant 16:102-107, 2010 103Unrelated-Donor Cord Blood for Nonmalignant DiseasesEach acceptable cord blood unit (CBU) was a 4/6 HLA
matchorbetterwith thepatient andachieved aminimum
precryopreservation cell dose of 2.5 107 total nucle-
ated cells (TNC)/kg. Double-unit CBT was done only
if no single unit $2.5 107 TNC/kg of recipient body
weight is available. Total cell dose for double-unit trans-
plants (UCB11UCB2) was required to be $3.7 107
TNC/kg of recipient body weight. These patients
received unmanipulated graftswithout ex vivo expansion
or T cell depletion. Cell dose escalation to facilitate
engraftment was permitted for patients with previous
graft failure. Therefore, UCB grafts used for transplan-
tation in this study contained after thawing a median
of 7.6 107 TNC (range: 2.8-15.0) and 4.0 105
CD34 cells (range: 1.3-19.9) per kilogram recipient
body weight.
Searches for unrelated CB donors were processed
through the StemCyte Cord Blood Bank. Units of
cord blood required a match of at least 4 of 6 HLA
loci based on antigen-level HLA-A and -B typing
and allele-level HLA-DRB1 typing. Matching at
HLA-C, -DQ, and -DP were not considered. Individ-
ual data sets were compiled and verified through the
audit processes of the Center for International Blood
and Marrow Transplant Research (CIBMTR).
Conditioning Regimen
Depending on the underlying disease, patients re-
ceived an antithymocyte globulin (ATG)-containing
conditioning regimen with or without total body irra-
diation (TBI) followed by UBT transplantation. The
specifics of conditioning regimen depends on the
nature of the disease for which transplant is being per-
formed, Lansky performance status, and age of the
patients. Conditioning consisted of i.v. busulfan (Bu)
14 mg/kg over 4 days (day 29 to 26) plus cyclophos-
phamide (Cy) 200 mg/kg over 4 days (day25 to22) in
37 transplants for thalassemia, 4 for immunodefi-
ciency, and 1 for a 7-month-old infant with osteopet-
rosis. Three recipients with SAA and 2 with FA
received fludarabine (Flu; 30 mg/m2/day 6 days)
and Cy (60 mg/kg/day 2 days). Regimens including
TBI were used for 2 transplants for osteopetrosis; 1 pa-
tient with SCID received ATG alone. The condition-
ing regimens used for retransplant in thalassemic
patients consisted of i.v. Bu 14 mg/kg over 4 days
(days 27 to 24) plus Cy 120 mg/kg over 2 days (days
23 to 22).
Hematopoietic Recovery and Engraftment
Myeloid engraftment was defined as 3 consecutive
days of an absolute neutrophil count (ANC)
$0.5 109/L. The day after the last day of red blood
cell (RBC) transfusion was recorded as the first day
of RBC transfusion independence. Platelet engraft-
ment was defined as 7 consecutive days of a plateletcount of$20 109/Lmaintained without transfusion.
In thalassemic patients with myeloid engraftment, des-
ferrioxamine was administered intravenously to accel-
erate the clearance of body iron deposits if serum
ferritin levels exceeded 2500 mg/L. Phlebotomy was
not justifiable when iron overload and anemia exist
simultaneously.
Chimerism Studies
Chimerism status was assessed analyzing short tan-
dem repeat (STR) polymorphisms. Peripheral blood
(PB) samples after transplantation were collected for
donor chimerism studies. Chimerism analyses of BM
erythroblasts were not routinely performed. Serial
STR polymerase chain reaction confirmed conversion
from mixed chimerism to a predominantly donor pro-
file on the day that the myeloid engraftment occurred,
on day 142, 1100, 1180, 1270, and 1360, 1.5 years
after transplantation, and yearly, thereafter. An addi-
tional test was done if clinically indicated. Total leuko-
cyte chimerismwas determined by analysis of STR loci
(Profiler Plus, Applied Biosystem, Foster City, CA).
GVHD Prophylaxis
GVHD prophylaxis consisted of antithymocyte
globulin (ATG), cyclosporine (CsA), and methylpred-
nisolone. The level of CsA was adjusted to between
200 and 400 ng/mL. Patients were evaluated for
aGVHD daily during initial hospitalization, at least
once weekly after initial discharge during the first 100
days, and at routine follow-up evaluations posttrans-
plant. aGVHD was staged according to Glucksberg’s
criteria, with histopathologic confirmation when pos-
sible, and an overall grade was assigned according to
the International Blood and Marrow Transplant
Research (IBMTR) severity index. Patients with clini-
cal stage II or later disease were treated initially with
methylprednisolone (.48 mg/m2 intravenously or
oral equivalent) daily for a minimum of 2 weeks prior
to tapering.
Statistical Analysis
Baseline characteristics of all patients were sum-
marized using descriptive statistics. Overall survival
(OS) was measured from transplantation until death
from any cause or last date of follow-up. Disease-free
survival (DFS) was defined as the time from transplan-
tation to relapse or death from any cause. Probabilities
of survival and TRM were evaluated by Kaplan-Meier
analysis. Patients who died without evidence of en-
graftment were censored at the time of death (n5 1).
Patients who had very slow engraftment (after day
42) or failed to have BM reconstitution of donor origin
were scored as having primary graft failure (n5 4).
Those with autologous recovery after primary engraft-
ment were scored as having secondary graft failure
Table 1. Demography of 45 Patients with Nonmalignant
Diseases for CBT
Characteristics of patients
undergone UCB transplant
Number of patient (%) or
median (range)
Number of patients 45
104 Biol Blood Marrow Transplant 16:102-107, 2010T.-H. Jaing et al.(n5 2). Pearson’s correlation coefficient was used to
estimate a correlation between nucleated cell dose
and CD34 cell dose. All statistical were performed
using SPSS for Windows (release 11.0.1; SPSS Inc.,
Chicago, IL).Median age in years (range) 4.5 (0.1-16.2)
Male: Female 27:18 (60%:40%)
Diagnosis
Transfusion-dependent thalassemia 32 (71%)
Severe aplastic anemia 3 (7%)
Fanconi anemia 2 (4%)
Infantile osteopetrosis 3 (7%)
Primary immunodeficiency 5 (11%)
Matching at antigen-level for HLA-A and -B and
allele-level for HLA-DRB1
Fully matched 11 (17%)
One mismatch 25 (40%)
Two mismatches 26 (41%)
Three mismatches 1 (2%)
ABO compatibility
Full match 25 (40%)
Minor mismatch 18 (28%)
Major mismatch 20 (32%)
Number of infused cells
Nucleated cells (107/kg) 7.6 (2.8-15.0)
CD34 cells (105/kg) 4.0 (1.3-19.9)
Conditioning regimen
Myeloablative 43 (86%)
Reduced intensity 7 (14%)
Cord blood units
Single-unit 37 (74%)
Double-unit 13 (26%)
UCB indicates umbilical cord blood; CBT, cord blood transplantation.RESULTS
Patient and Cord Blood Characteristics
A total of 50 UCB transplants were performed
between August 2003 and February 2009. Patient
characteristics and treatment of the 45 recipients are
shown in Table 1. Among donor-recipient matches,
36 matched at 5 or 6 HLA loci and 26 matched at 4
HLA loci. One matched at 3 HLA loci with 2
GVHD mismatches. Reduced-intensity conditioning
(RIC) regimens were used in 7 patients (5 with primary
immunodeficiency and 2 with FA). In 32 patients with
thalassemia, 21 patients were classified as Pesaro I, 9
were Pesaro II, and 2 were previously unavailable.
There are 27 patients (84%) who are alive and transfu-
sion-independent after a median follow-up of 27
months (range: 3-66 months). Five patients with thal-
assemia underwent retransplantation for graft failure.
Three patients had primary graft failure and the other
2 had secondary graft failure. Table 2 summarized the
5 patients’ characteristics and outcome.
Of the 45 patients, 12 received 2 UCB units. One
of these 12 patients received a second transplant 10
months after first transplantation because of secondary
graft failure. Forty-four patients achieved neutrophil
engraftment at a median of day 16 (range: 10-46
days). Incidence of neutrophil engraftment by day 42
was 88% (95% confidence interval [CI]5 0.76-0.94).
Median time to platelet engraftment was 48 days
(range: 24-117 days). Incidence of platelet engraftment
by day 60 was 82% (95% CI5 0.67-0.91) in 39 evalu-
able patients. There is a positive linear correlation
between CD34 and nucleated cell doses, but the corre-
lation was not statistically significant (R5 0.267;
P5 .06).aGVHD and Chronic GVHD (cGVHD)
aGVHD occurred in 42 patients and was scored as
grade I (n5 8), grade II (n5 15), grade III (n5 16), or
grade IV (n5 3) disease. By day 100 after transplanta-
tion, incidences of grade II-IV and grade III-IV
aGVHD was 76% (95% CI5 0.65-0.82) and 42%
(95% CI5 0.33-0.51), respectively. Skin was the or-
gan most likely to be affected, with mild to moderate
disease in the majority of patients (Table 3).
Of the evaluable patients, the incidence of
cGVHDwas 35% (95%CI5 0.29-0.42) at 1 year after
transplantation. Of the 14 patients who developed
cGVHD, extensive disease was found in 1 patientcompared with limited disease in 13. Of the 45 total
patients, 40 (89%) were alive and disease-free with
a Lansky performance score .80% at last follow-up
(range: 3 and 66 months; median, 25 months).
Disease Response and Survival Analysis
The estimated 5-year OS and PFS rates were
88.1% and 77.1%, respectively. The incidence of
TRM 2 years posttransplant was 12.0 % (Figure 1).
Initial multivariate analysis looked for differences be-
tween transplant-related parameters and the intention
of finding no significant differences. Therefore, uni-
variate analyses were not conducted.
At the time of writing, 40 of the 45 patients are
alive after UBT transplants. Three patients died dur-
ing the hospital stay, with 2 dying from bleeding com-
plications that developed from thrombocytopenia and
1 from sepsis. At 11 months posttransplant, 1 patient
died of alveolar hemorrhage secondary to Evans’ syn-
drome. At 14 months posttransplant, 1 patient died
from an accidental head injury.DISCUSSION
This trial involved 45 pediatric patients with
nonmalignant diseases, 40 of whom were transfu-
sion-dependent at study entry. TheChangGung Pedi-
atric Hematopoietic Stem Cell Transplantation
Table 2. Characteristics of Five Patients with Thalassemia Undergoing Retransplant for First Graft Failure
UPN 23 24 27 29 63
Characteristics of first transplants
Diagnosis b/b thalassemia b-thalassemia/Hb E b-thalassemia/Hb E b/b thalassemia b/b thalassemia
Donor type Single unrelated donor UCB 2 unrelated donor UCB Single unrelated donor UCB 2 unrelated donor UCB Single UCB
Conditioning regimen for first SCT Bu 14/Cy 200 /ATG Bu 14/Cy 200 /ATG Bu 14/Cy 200 /ATG Bu 14/Cy 200 /ATG Bu 14/Cy 200 /ATG
Number of HLA mismatching (loci)
HLA-A, B antigen 1 0 0 1 (donor 1)
0 (donor 2)
2
HLA-DRB1 allele 0 0 1 0 (donor 1)
1 (donor 2)
0
Infused TNC (107/kg) 6.95 6.31 4.80 15.95 5.36
Infused CD34+ (105/kg) 2.47 3.95 1.74 7.21 2.56
First graft failure Primary Secondary Primary Primary Secondary
Interval between transplants (mo) 7 10 10 1.5 8
Characteristics of second transplants
Donor type 2 unrelated donor UCB 2 unrelated donor UCB 2 unrelated donor UCB G-PBSC from haploidentical mother 2 UCB
Conditioning regimen for second SCT Bu 14/Cy 120 /ATG Bu 14/Cy 120 /ATG Bu 14/Cy 120 /ATG Bu 14/Cy 120 Bu 14/Cy 120 /ATG
Number of HLA mismatching (loci)
HLA-A, B antigen 0 (donor 1)
0 (donor 2)
0 (donor 1)
0 (donor 2)
1 (donor 1)
2 (donor 2)
2 2 (donor 1)
2 (donor 2)
HLA-DRB1 allele 1 (donor 1)
1 (donor 2)
1 (donor 1)
1 (donor 2)
1 (donor 1)
2 (donor 2)
0 0 (donor 1)
0 (donor 2)
Infused TNC (107/kg) 7.16 8.07 14.3 364 9.72
Infused CD34+ (105/kg) 4.02 5.07 7.58 161 5.04
Neutrophil engraftment Day +15 Day +23 Day +26 Day +11 Day +17
Platelet engraftment Day +33 Day +61 Day +53 Day +65 Day +61
Acute GVHD
Maximum clinical grade II I II II I
Site(s) involved Skin Skin Skin Skin, GI Skin
Chronic GVHD Limited Limited Limited Extensive Limited
Transplantation-related complications Evans’ syndrome BKV-associated HC No CMV reactivation No
Outcome Transfusion -independent Transfusion -independent Transfusion -independent Transfusion -independent Transfusion -independent
Chimerism status
Day of neutrophil engraftment 93.5% donor 1 96.6% donor 1 85.4% donor 1 100% donor 60.9% donor 1
30.1% donor 2
Latest follow-up 100% donor 1 100% donor 1 100% donor 1 100% donor 60.1% donor 1
39.9% donor 2
UCB indicates umbilical cord blood; HLA, human leucocyte antigen; G-PBPC, granulocyte colony stimulating factor mobilized peripheral blood stem cell; Bu, busulfan; Cy, cyclophosphamide; GVHD, graft-versus-host
disease; BKV-associated HC, BK virus-associated hemorrhagic cystitis; CMV, cytomegalovirus; ATG, antithymocyte globulin.
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Figure 1. Kaplan-Meier analyses of 45 patients who underwent unre-
lated cord blood transplantation. (A) Five-year disease-free survival
and (B) 2-year treatment-related mortality.
Table 3. Clinical Grade of Acute GVHD by Organ System
Severity Skin GI Liver Overall
Grade I 8 0 0 8
Grade II 15 1 1 15
Grade III 16 3 2 16
Grade IV 3 3 3 3
Total 42 7 6 42
GI indicates gastrointestinal tract; GVHD, graft-versus-host disease.
106 Biol Blood Marrow Transplant 16:102-107, 2010T.-H. Jaing et al.(HSCT) Program has an active protocol for using
unrelated donor UCB for transplantation as an alter-
native source of stem cells when matched unrelated
donor marrow is not available. For patients with trans-
fusion-dependent thalassemia, the approach was based
on the assumption that the risks associated with UCB
transplantation could be counteracted by iron over-
load leading to organ dysfunction and by transfu-
sion-associated viral infection.These hazards are
particularly objectionable in young patients with po-
tential for a long life span. Older patients generally
have more advanced disease with both disease- and
treatment-related organ complications, mainly be-
cause of prolonged iron overload. In our study, all graft
failures occurred in patients with thalassemia (6/32,
19%) who were above the age of 6 years. It has been
suggested that HSCT has generally been unsuccessful
when applied to patients with thalassemia who have
a history of multiple transfusions [2]. Therefore, it
was decided for this study that early transplantation
of unrelated donor UCB could be conducted in young
patients who had received few transfusions.
BM transplantation has emerged as a major thera-
peutic option for a number of nonmalignant diseases
affecting BM and leading to significant clinical mani-
festations affecting other organs. In most instances,
the goal of transplantation is to provide stable long-
term engraftment and amelioration of disease pheno-
type [3]. Although delayed or failed engraftment may
be attributable to the lower nucleated cell dose in
UCB graft, other characteristics of UCB progenitor
cells may affect homing and maturation in the recipi-
ent and confound correlations with engraftment [4].
When high cell doses are used, UCB transplantation
has been shown to achieve outstanding survival in pa-
tients with nonmalignant diseases such as thalassemia
[5,6]. The results of our study keenly imply that suc-
cessful outcome reported for a large number of such
serious, nonmalignant disorders.
The main limitation of unrelated donor BMT is
that, using stringent criteria, only about one-third of
patients who started the search find a suitable donor
in a median of 3 to 4 months. One possibility to in-
crease donor pools would be to adopt less stringent cri-
teria for HLA matching so donor acceptability would
allow disparity in 1 or 2 alleles.
At present, most banks match UCB donors for
respective recipients by HLA-A, -B low-resolutiontyping and -DRB1 high-resolution typing [1,7].
With such a large supply and flexibility ofHLAmatch-
ing, collecting more CBU should pose no difficulty in
finding compatible donors. Cell number seems to be
quite important; perhaps more so than a high degree
ofHLAmatch. In our previous study, it has been shown
that higher prefreezeTNC andCD341 cell doses were
associated with cord predominance [8]. However,
CD34 count seems to be a better quantitative indicator
of success than nucleated cell count [9]. Our study has
demonstrated a higher cell dose supports higher levels
of engraftment. Furthermore, double-unit transplants
may reduce the time to engraftment and thus reduce
TRM [10-12]. High-resolution HLA typing has en-
abled physicians to perform transplants from unrelated
volunteer donors for thalassemic patients with results
comparable with those obtained employing an HLA-
identical sibling [13].
Improved RBC transfusion schedules and iron
chelation therapy have allowed children with thalasse-
mia to avoid serious deformities and to have an im-
proved life expectancy. When a matched-related or
matched-unrelated adult donor cannot be found, it is
debated that matched unrelated donor UCB should
be used. The result of discussion is always that there
are many clinical variables to create rules, such as
Biol Blood Marrow Transplant 16:102-107, 2010 107Unrelated-Donor Cord Blood for Nonmalignant Diseasesuniversally poor outcome with conventional treatment
for patients with increasing age [14] and the optimal
indication for transplantation in young children with
transfusion-dependent thalassemia.
Improvements in conservative treatment have con-
siderably improved the prognosis of patients with non-
malignant diseases such as thalassemia. However,
disease- and treatment-related complications progress
over time in many patients, causing severe morbidity
and shortening life expectancy even in patients with ac-
cess to good medical treatment [15,16]. There is no
reason to deny these patients the advantages of a life
free from daily tedious, expensive, and uncomfortable
therapy. Delaying transplantation until the patient is in
a risk category substantially reduces the probability of
transplant success and jeopardizes reversibility of
organ damage. Patients without an HLA-identical
related donor who have a well-selected unrelated
donor should also be considered for transplantation
with UCB.CONCLUSIONS
In experienced hands and highly specialized cen-
ters, use of unrelated donor UCB transplantation
may create fundamental new opportunities for treat-
ment of nonmalignant diseases requiring expedient
HSCT to prevent irreversible disease progression.ACKNOWLEDGMENTS
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